[1]
L. Peng, J. He, Y. Zheng, and Q. Zeng, “Effects of monoclonal antibody daratumumab combined with ixazomib-based treatment regimen on survival of patients with relapsed/refractory multiple myeloma”, Vojnosanit Pregl, vol. 82, no. 04, Apr. 2025, doi: 10.2298/VSP231207016P.